Efavirenz limits HIV infection by :
Binding to active site of HIV reverse transcriptase
Impairing the binding of HIV virion to CD4 receptors on T–cells
Inhibiting the HIV protease
Serving as an allosteric inhibitor of HIV reverse transcriptase